JP2014513088A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513088A5 JP2014513088A5 JP2014506794A JP2014506794A JP2014513088A5 JP 2014513088 A5 JP2014513088 A5 JP 2014513088A5 JP 2014506794 A JP2014506794 A JP 2014506794A JP 2014506794 A JP2014506794 A JP 2014506794A JP 2014513088 A5 JP2014513088 A5 JP 2014513088A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- period
- dose
- composition according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 210000003719 b-lymphocyte Anatomy 0.000 claims 11
- 230000002411 adverse Effects 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 210000005259 peripheral blood Anatomy 0.000 claims 3
- 239000011886 peripheral blood Substances 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 206010003062 Apraxia Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000027765 speech disease Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161479961P | 2011-04-28 | 2011-04-28 | |
| US61/479,961 | 2011-04-28 | ||
| PCT/EP2012/001857 WO2012146394A1 (en) | 2011-04-28 | 2012-04-30 | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017194928A Division JP6539709B2 (ja) | 2011-04-28 | 2017-10-05 | 潜在的有害作用リスクのある患者にＣＤ１９ｘＣＤ３二特異性抗体を投与するための投薬レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513088A JP2014513088A (ja) | 2014-05-29 |
| JP2014513088A5 true JP2014513088A5 (enExample) | 2015-06-25 |
| JP6276175B2 JP6276175B2 (ja) | 2018-02-07 |
Family
ID=46178514
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506794A Active JP6276175B2 (ja) | 2011-04-28 | 2012-04-30 | 潜在的有害作用リスクのある患者にＣＤ１９ｘＣＤ３二特異性抗体を投与するための投薬レジメン |
| JP2017194928A Active JP6539709B2 (ja) | 2011-04-28 | 2017-10-05 | 潜在的有害作用リスクのある患者にＣＤ１９ｘＣＤ３二特異性抗体を投与するための投薬レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017194928A Active JP6539709B2 (ja) | 2011-04-28 | 2017-10-05 | 潜在的有害作用リスクのある患者にＣＤ１９ｘＣＤ３二特異性抗体を投与するための投薬レジメン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10191034B2 (enExample) |
| EP (2) | EP2701741B1 (enExample) |
| JP (2) | JP6276175B2 (enExample) |
| KR (2) | KR102147533B1 (enExample) |
| CN (2) | CN103648529A (enExample) |
| AU (2) | AU2012247762B2 (enExample) |
| CA (1) | CA2832360C (enExample) |
| ES (1) | ES2806142T3 (enExample) |
| MX (1) | MX354371B (enExample) |
| WO (1) | WO2012146394A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012009778A2 (pt) * | 2009-10-27 | 2017-06-13 | Micromet Ag | regime de dosagem para administrar um anticorpo biespecífico de cd19xcd3 |
| EP2701741B1 (en) * | 2011-04-28 | 2020-06-10 | Amgen Research (Munich) GmbH | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| CN105073776B (zh) * | 2012-11-13 | 2019-04-12 | 拜恩科技股份公司 | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| JO3529B1 (ar) | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| EP2970486B1 (en) | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| EP3936521B1 (en) * | 2013-03-15 | 2026-02-11 | Xencor, Inc. | Heterodimeric proteins |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| FI3531133T3 (fi) | 2014-05-30 | 2023-11-02 | Amgen Res Munich Gmbh | Prekursori-b-solujen akuutin lymfoblastisen leukemian potilaiden riskiluokittelu |
| JP2017536830A (ja) | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３及びｃｄ３８に結合するヘテロ二量体抗体 |
| SG11201704283PA (en) | 2014-11-26 | 2017-06-29 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| WO2016105450A2 (en) | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| US10227411B2 (en) | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| CA2991799A1 (en) | 2015-07-15 | 2017-01-19 | Zymeworks Inc. | Drug-conjugated bi-specific antigen-binding constructs |
| ES2980794T3 (es) | 2015-09-15 | 2024-10-03 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| US11827688B2 (en) * | 2016-06-02 | 2023-11-28 | Immunocore Limited | Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein |
| MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
| KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| BR112019007281A2 (pt) | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| AU2018366199A1 (en) | 2017-11-08 | 2020-05-28 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-PD-1 sequences |
| AU2018390418B2 (en) | 2017-12-19 | 2023-12-21 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| AU2019247415A1 (en) | 2018-04-04 | 2020-10-22 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質 |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| TW202028244A (zh) * | 2018-10-09 | 2020-08-01 | 美商建南德克公司 | 用於確定突觸形成之方法及系統 |
| WO2020180726A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| EP3962948A1 (en) * | 2019-04-30 | 2022-03-09 | Amgen Research (Munich) GmbH | Means and methods of treating burkitt lymphoma or leukemia |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| WO2021150824A1 (en) * | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| EP4240491A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19 binding molecules and uses thereof |
| AU2021374083A1 (en) | 2020-11-06 | 2023-06-01 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
| KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
| US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| CN120548186A (zh) * | 2022-12-21 | 2025-08-26 | 得克萨斯大学体系董事会 | 功能增强的表达cd3和itcr的工程化的自然杀伤细胞用于过继免疫疗法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| KR100508289B1 (ko) * | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도 |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| SI1976886T1 (sl) | 2005-12-16 | 2015-03-31 | Amgen Research (Munich) Gmbh | Sredstva in postopki za zdravljenje tumorskih bolezni |
| SG10201808730VA (en) | 2007-04-03 | 2018-11-29 | Amgen Res Munich Gmbh | Cross-species-specific binding domain |
| CN109456410B (zh) | 2007-04-03 | 2022-01-28 | 安进研发（慕尼黑）股份有限公司 | 跨物种特异性CD3-ε结合结构域 |
| HRP20151168T1 (hr) * | 2008-11-07 | 2015-12-04 | Amgen Research (Munich) Gmbh | Lijeäśenje akutne limfoblastiäśne leukemije |
| BR112012009778A2 (pt) * | 2009-10-27 | 2017-06-13 | Micromet Ag | regime de dosagem para administrar um anticorpo biespecífico de cd19xcd3 |
| SMT201700250T1 (it) * | 2010-11-10 | 2017-07-18 | Amgen Res Munich Gmbh | Prevenzione di effetti avversi provocati da domini leganti cd3 specifici |
| EP2701741B1 (en) * | 2011-04-28 | 2020-06-10 | Amgen Research (Munich) GmbH | Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects |
| US9486475B2 (en) * | 2013-02-08 | 2016-11-08 | Amgen Research (Munich) Gmbh | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
-
2012
- 2012-04-30 EP EP12724289.9A patent/EP2701741B1/en active Active
- 2012-04-30 JP JP2014506794A patent/JP6276175B2/ja active Active
- 2012-04-30 WO PCT/EP2012/001857 patent/WO2012146394A1/en not_active Ceased
- 2012-04-30 MX MX2013012448A patent/MX354371B/es active IP Right Grant
- 2012-04-30 ES ES12724289T patent/ES2806142T3/es active Active
- 2012-04-30 KR KR1020137031150A patent/KR102147533B1/ko active Active
- 2012-04-30 EP EP20178760.3A patent/EP3753572A1/en active Pending
- 2012-04-30 CN CN201280020887.XA patent/CN103648529A/zh active Pending
- 2012-04-30 US US14/113,755 patent/US10191034B2/en active Active
- 2012-04-30 AU AU2012247762A patent/AU2012247762B2/en active Active
- 2012-04-30 CA CA2832360A patent/CA2832360C/en active Active
- 2012-04-30 CN CN201710597419.3A patent/CN107303387A/zh active Pending
- 2012-04-30 KR KR1020207023808A patent/KR102345943B1/ko active Active
-
2017
- 2017-08-21 AU AU2017218919A patent/AU2017218919A1/en not_active Abandoned
- 2017-10-05 JP JP2017194928A patent/JP6539709B2/ja active Active
-
2018
- 2018-12-12 US US16/217,366 patent/US11579142B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Decker et al. | The psychobiological links between chronic stress‐related diseases, periodontal/peri‐implant diseases, and wound healing | |
| Duhen et al. | IL-1β promotes the differentiation of polyfunctional human CCR6+ CXCR3+ Th1/17 cells that are specific for pathogenic and commensal microbes | |
| MX354371B (es) | Régimen de dosificación para administrar un anticuerpo biespecífico cd19xcd3 a pacientes en riesgo de efectos adversos potenciales. | |
| Zhao et al. | The peroxisome-proliferator activated receptor-γ agonist pioglitazone modulates aberrant T cell responses in systemic lupus erythematosus | |
| JP2016500698A5 (enExample) | ||
| JP2014530226A5 (enExample) | ||
| Kumar et al. | IL-22: an evolutionary missing-link authenticating the role of the immune system in tissue regeneration | |
| Aryankalayil et al. | Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells | |
| Takeuchi et al. | Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study) | |
| JP2011126917A5 (enExample) | ||
| SG179204A1 (en) | Dosage regimen for administering a cd19xcd3 bispecific antibody | |
| JP2018500276A5 (enExample) | ||
| Kremer et al. | FRI0090 Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis | |
| JP2016516985A5 (enExample) | ||
| Fox et al. | Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients | |
| Park et al. | PD-1 deficiency protects experimental colitis via alteration of gut microbiota | |
| Sawant et al. | Does HbF induction by hydroxycarbamide work through MIR210 in sickle cell anaemia patients? | |
| Han et al. | Epigallocatechin gallate attenuates overload‑induced cardiac ECM remodeling via restoring T cell homeostasis | |
| Schmidt et al. | Interleukin 1 receptor contributes to methamphetamine-and sleep deprivation-induced hypersomnolence | |
| Al-Fadhli et al. | Evaluation of leptin, interleukin–1 beta and tumor necrosis factor alpha in serum of malaria patients as prognostic markers of treatment outcome | |
| Gordon et al. | OP0044 Effects of Atacicept on Disease Activity in Patients with Moderate to Severe Systemic Lupus Erythematosus: APRIL-SLE Randomized Trial | |
| US10226470B2 (en) | DGAT1 inhibition for treatment of demyelinating inflammatory disease | |
| Jenkins et al. | DI-010 A systematic literature review of antimicrobial stability data in Elastomeric devices | |
| FI3298042T3 (fi) | B-solujen vähentyminen diagnostisena merkkinä | |
| De Pablo et al. | AB0279 Incidence of diabetes and effect of etanercept and adalimumab on hba1c over 1 year: data from a randomised trial in patients with rheumatoid arthritis |